

# Homeland Security Presidential Directive-10 “Biodefense for the 21<sup>st</sup> Century”

---

- Threat Awareness
- Prevention and Protection
- Surveillance and Detection
- Response and Recovery
  - Response Planning
  - Mass Casualty Care
  - Risk Communication
  - **Medical Countermeasure Development**
  - Decontamination



## NIAID Strategic Plan for Biodefense Research



## NIAID Biodefense Research Agenda for CDC Category A Agents



## NIAID Biodefense Research Agenda for CDC Category A Agents

### Progress Report



August 2003



## NIAID Biodefense Research Agenda for Category B and C Priority Pathogens

### Progress Report



June 2004



## NIAID Biodefense Research Agenda for Category B and C Priority Pathogens




January 2003

# Biodefense Countermeasure Development: Key Achievements

---


## Smallpox

- More than 300 million doses of smallpox vaccine now available
- "Next-generation" vaccine (MVA) in advanced testing
- Antiviral drug development, e.g. oral cidofovir



## Anthrax

- New vaccine (rPA) tested and procured under Project Bioshield
- Development of novel antitoxins, e.g. monoclonal/polyclonal antibodies




# Biodefense Countermeasure Development: Key Achievements

---


## Ebola

- Vaccine in human trials at NIAID Vaccine Research Center




## Botulinum Toxin

- Development of vaccine and monoclonal/polyclonal antibodies



## Influenza

- Development of vaccines against potential pandemic strains



# Global Examples of Emerging and Re-Emerging Infectious Diseases

